Revisiting the immunomodulators tacrolimus, methotrexate, and mycophenolate mofetil: Their mechanisms of action and role in the treatment of IBD

Inflammatory Bowel Diseases

Volumn 12, Issue 4, 2006, Pages 311-327

  Van Dieren, Jolanda M ^a   Kuipers, Ernst J ^a   Samsom, Janneke N ^a   Nieuwenhuis, Edward E ^a   Van Der Woude, C Janneke ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Immunomodulation; Inflammatory bowel disease; Mechanism of action; Therapy

Indexed keywords

BUDESONIDE; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOMODULATING AGENT; MESALAZINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

DRUG EFFECT; DRUG MECHANISM; EFFECTOR CELL; ENTERITIS; ENVIRONMENTAL FACTOR; ENZYME ACTIVATION; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INFLAMMATORY CELL; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION; UNSPECIFIED SIDE EFFECT;

HUMANS; IMMUNITY, CELLULAR; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; METHOTREXATE; MYCOPHENOLIC ACID; PRODRUGS; TACROLIMUS; TREATMENT OUTCOME;

EID: 33646767110     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/01.MIB.0000209787.19952.53     Document Type: Review

References (212)

1. Papadakis KA, Targan SR. Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med. 2000;51:289-298.
2. Neurath MF. Mucosal immunity in Crohn's disease. Inflamm Bowel Dis. 2004;10:S29-S31.
3. Nieuwenhuis EE, Blumberg RS. The role of the epithelial barrier in inflammatory bowel disease. In: Blumberg RS, Neurath MF, eds. Immune Mechanisms in Inflammatory Bowel Disease. New York: Springer Science, Landes Bioscience; 2005:109-116.
4. Rieux-Laucat F, Le DF, Hivroz C, et al. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science. 1995;268:1347-1349.
5. Ina K, Itoh J, Fukushima K, et al. Resistance of Crohn's disease T cells to multiple apoptotic signals is associated with a Bcl-2/Bax mucosal imbalance. J Immunol. 1999;163:1081-1090.
6. Lichtenberger GS, Flavell RA, Alexopoulou L. Innate immunity and apoptosis in FBD. Inflamm Bowel Dis. 2004;10:S58-S62.
7. Neurath MF, Finotto S, Fuss I, et al. Regulation of T-cell apoptosis in inflammatory bowel disease: to die or not to die, that is the mucosal question. Trends Immunol. 2001;22:21-26.
8. Van den Brande JM, Braat H, van den Brink GR, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology. 2003;124:1774-1785.
9. Binion DG, West GA, Volk EE, et al. Acquired increase in leucocyte binding by intestinal microvascular endothelium in inflammatory bowel disease. Lancet. 1998;352:1742-1746.
10. Jones SC, Banks RE, Haidar A, et al. Adhesion molecules in inflammatory bowel disease. Gut. 1995;36:724-730.
11. van Assche G, Rutgeerts P. Antiadhesion molecule therapy in inflammatory bowel disease. Inflamm Bowel Dis. 2002;8:291-300.
12. van Deventer SJ, Volfova M, Flisiak R, et al. A phase 2 dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis [abstract 490]. Gastroenterology. 2005;128:A-74.
13. Gordon FH, Lai CW, Hamilton MI, et al. A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease. Gastroenterology. 2001;121:268-274.
14. van Assche G, van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med. 2005;353:362-368.
15. Bianchi M, Bloom O, Raabe T, et al. Suppression of proinflammatory cytokines in monocytes by a tetravalent guanylhydrazone. J Exp Med. 1996;183:927-936.
16. Cohen PS, Nakshatri H, Dennis J, et al. CNI-1493 inhibits monocyte/macrophage tumor necrosis factor by suppression of translation efficiency. Proc Natl Acad Sci U S A. 1996;93:3967-3971.
17. Hommes D, van den Blink B, Plasse T, et al. Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. Gastroenterology. 2002;122:7-14.
18. Schreiber S, Nikolaus S, Hampe J. Activation of nuclear factor kappa B inflammatory bowel disease. Gut. 1998;42:477-484.
19. Rogler G, Brand K, Vogl D, et al. Nuclear factor kappaB is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology. 1998;115:357-369.
20. Neurath MF, Becker C, Barbulescu K. Role of NF-kappaB in immune and inflammatory responses in the gut. Gut. 1998;43:856-860.
21. Yin MJ, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature. 1998;396:77-80.
22. Neurath MF, Pettersson S, Meyer zum Buschenfelde KH, et al. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice. Nat Med. 1996;2:998-1004.
23. Fuss IJ, Neurath M, Boirivant M, et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol. 1996;157:1261-1270.
24. Niessner M, Volk BA. Altered Th1/Th2 cytokine profiles in the intestinal mucosa of patients with inflammatory bowel disease as assessed by quantitative reversed transcribed polymerase chain reaction (RT-PCR). Clin Exp Immunol. 1995;101:428-435.
25. Ricart E, Panaccione R, Loftus EV, et al. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients. Am J Gastroenterol. 2001;96:722-729.
26. Mannon PJ, Fuss IJ, Mayer L, et al. Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med. 2004;351:2069-2079.
27. Sandborn WJ. How future tumor necrosis factor antagonists and other compounds will meet the remaining challenges in Crohn's disease. Rev Gastroenterol Disord. 2004;4:S25-S33.
28. Kuhn R, Lohler J, Rennick D, et al. Interleukin-10-deficient mice develop chronic enterocolitis. Cell. 1993;75:263-274.
29. Meresse B, Rutgeerts P, Malchow H, et al. Low ileal interleukin 10 concentrations are predictive of endoscopic recurrence in patients with Crohn's disease. Gut. 2002;50:25-28.
30. Braat H, Rottiers P, Huyghebaart N, et al. Interleukin-10 producing Lactococcus lactis for the treatment of Crohn's disease [abstract 685]. Gastroenterology. 2005;128:A-104.
31. van Deventer SJ, Elson CO, Fedorak RN. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group. Gastroenterology. 1997;113:383-389.
32. Steidler L, Hans W, Schotte L, et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science. 2000;289:1352-1355.
33. Hahm KB, Im YH, Parks TW, et al. Loss of transforming growth factor beta signalling in the intestine contributes to tissue injury in inflammatory bowel disease. Gut. 2001;49:190-198.
34. Oz HS, Ray M, Chen TS, et al. Efficacy of a transforming growth factor beta 2 containing nutritional support formula in a murine model of inflammatory bowel disease. J Am Coll Nutr. 2004;23:220-226.
35. Babyatsky MW, Rossiter G, Podolsky DK. Expression of transforming growth factors alpha and beta in colonic mucosa in inflammatory bowel disease. Gastroenterology. 1996;110:975-984.
36. Del Zotto B, Mumolo G, Pronio AM, et al. TGF-beta1 production in inflammatory bowel disease: differing production patterns in Crohn's disease and ulcerative colitis. Clin Exp Immunol. 2003;134:120-126.
37. Monteleone G, Kumberova A, Croft NM, et al. Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease. J Clin Invest. 2001;108:601-609.
38. Fung JJ. Tacrolimus and transplantation: a decade in review. Transplantation. 2004;77:41-43.
39. Van Thiel DH, Carroll P, bu-Elmagd K, et al. Tacrolimus (FK 506), a treatment for primary sclerosing cholangitis: results of an open-label preliminary trial. Am J Gastroenterol. 1995;90:455-459.
40. Klee CB, Draetta GF, Hubbard MJ. Calcineurin. Adv Enzymol Relat Areas Mol Biol. 1988;61:149-200.
41. Dumont FJ, Staruch MJ, Koprak SL, et al. Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin. J Immunol. 1990;144:251-258.
42. Khanna AK. Mechanism of the combination immunosuppressive effects of rapamycin with either cyclosporine or tacrolimus. Transplantation. 2000;70:690-694.
43. Hashimoto Y, Matsuoka N, Kawakami A, et al. Novel immunosuppressive effect of FK506 by augmentation of T cell apoptosis. Clin Exp Immunol. 2001;125:19-24.
44. Migita K, Origuchi T, Kawabe Y, et al. FK506 markedly enhances apoptosis of antigen-stimulated peripheral T cells by down-regulation of Bcl-xL. Transplantation. 1999;68:1018-1023.
45. Brunner T, Yoo NJ, LaFace D, et al. Activation-induced cell death in murine T cell hybridomas. Differential regulation of Fas (CD95) versus Fas ligand expression by cyclosporin A and FK506. Int Immunol. 1996;8:1017-1026.
46. Hortelano S, Lopez-Collazo E, Bosca L. Protective effect of cyclosporin A and FK506 from nitric oxide-dependent apoptosis in activated macrophages. Br J Pharmacol. 1999;126:1139-1146.
47. Kantrow SP, Gierman JL, Jaligam VR, et al. Regulation of tumor necrosis factor cytotoxicity by calcineurin. FEBS Lett. 2000;483:119-124.
48. Strauss G, Osen W, Debatin KM. Induction of apoptosis and modulation of activation and effector function in T cells by immunosuppressive drugs. Clin Exp Immunol. 2002;128:255-266.
49. Crenesse D, Laurens M, Heurteaux C, et al. Rat liver ischemia- reperfusion-induced apoptosis and necrosis are decreased by FK506 pretreatment. Eur J Pharmacol. 2003;473:177-184.
50. Yang CW, Ahn HJ, Han HJ, et al. Pharmacological preconditioning with low-dose cyclosporine or FK506 reduces subsequent ischemia/ reperfusion injury in rat kidney. Transplantation. 2001;72:1753-1759.
51. Sekigawa I, Hishikawa T, Kaneko H, et al. FK506 can inhibit apoptotic cell death induced by the HIV-1 envelope glycoprotein gp120. AIDS. 1994;8:1623-1624.
52. Furuichi Y, Katsuta K, Maeda M, et al. Neuroprotective action of tacrolimus (FK506) in focal and global cerebral ischemia in rodents: dose dependency, therapeutic time window and long-term efficacy. Brain Res. 2003;965:137-145.
53. Chuvpilo S, Jankevics E, Tyrsin D, et al. Autoregulation of NFATc1/A expression facilitates effector T cells to escape from rapid apoptosis. Immunity. 2002;16:881-895.
54. Luk JM, Lai W, Tam P, et al. Suppression of cytokine production and cell adhesion molecule expression in human monocytic cell line THP-1 by Tripterygium wilfordii polysaccharide moiety. Life Sci. 2000;67:155-163.
55. Weimer R, Melk A, Daniel V, et al. Switch from cyclosporine A to tacrolimus in renal transplant recipients: impact on Th1, Th2, and monokine responses. Hum Immunol. 2000;61:884-897.
56. Arreaza G, Yoshikawa N, Mukuta T, et al. Expression of intercellular adhesion molecule-1 on human thyroid cells from patients with autoimmune thyroid disease: study of thyroid xenografts in nude and severe combined immunodeficient mice and treatment with FK-506. J Clin Endocrinol Metab. 1995;80:3724-3731.
57. Freyschmidt-Paul P, Ziegler A, McElwee KJ, et al. Treatment of alopecia areata in C3H/HeJ mice with the topical immunosuppressant FK506 (tacrolimus). Eur J Dermatol. 2001;11:405-409.
58. Hiromatsu Y, Sato M, Koga M, et al. Inhibitory effect of FK506 on intercellular adhesion molecule-1 (ICAM-1) expression on cultured thyroid cells. Kurume Med J. 1994;41:73-79.
59. Nemoto H, Nemoto K, Sugimoto H, et al. FK506 suppressed the inflammatory change of EAM in SJL/J mice. J Neurol Sci. 2001;193:7-11.
60. Squadrito F, Altavilla D, Squadrito G, et al. Tacrolimus limits polymorphonuclear leucocyte accumulation and protects against myocardial ischaemia- reperfusion injury. J Mol Cell Cardiol. 2000;32:429-440.
61. Thomson AW, Nalesnik MA, Rilo HR, et al. ICAM-1 and E-selectin expression in lesional biopsies of psoriasis patients responding to systemic FK 506 therapy. Autoimmunity. 1993;15:215-223.
62. Munakata Y, Saito T, Watanabe T, et al. Rapid inhibitory effect of tacrolimus on T cell migration by suppressing CD29-related functions. Clin Exp Rheumatol. 2004;22:197-204.
63. Matsuda S, Shibasaki F, Takehana K, et al. Two distinct action mechanisms of immunophilin-ligand complexes for the blockade of T-cell activation. EMBO Rep. 2000;1:428-434.
64. Matsuda S, Koyasu S. Regulation of MAPK signaling pathways through immunophilin-ligand complex. Curr Top Med Chem. 2003;3:1358-1367.
65. Yang CW, Ahn HJ, Jung JY, et al. Preconditioning with cyclosporine A or FK506 differentially regulates mitogen-activated protein kinase expression in rat kidneys with ischemia/reperfusion injury. Transplantation. 2003;75:20-24.
66. Frantz B, Nordby EC, Bren G, et al. Calcineurin acts in synergy with PMA to inactivate I kappa B/MAD3, an inhibitor of NF-kappa B. EMBO J. 1994;13:861-870.
67. Biswas G, Anandatheerthavarada HK, Zaidi M, et al. Mitochondria to nucleus stress signaling: a distinctive mechanism of NFkappaB/Rel activation through calcineurin-mediated inactivation of IkappaBbeta. J Cell Biol. 2003;161:507-519.
68. Kanno T, Siebenlist U. Activation of nuclear factor-kappaB via T cell receptor requires a Raf kinase and Ca2+ influx. Functional synergy between Raf and calcineurin. J Immunol. 1996;157:5277-5283.
69. Steffan NM, Bren GD, Frantz B, et al. Regulation of IkB alpha phosphorylation by PKC- and Ca(2+)-dependent signal transduction pathways. J Immunol. 1995;155:4685-4691.
70. Trushin SA, Pennington KN, Algeciras-Schimnich A, et al. Protein kinase C and calcineurin synergize to activate IkappaB kinase and NF-kappaB in T lymphocytes. J Biol Chem. 1999;274:22923-22931.
71. Cristillo AD, Bierer BE. Identification of novel targets of immunosuppressive agents by cDNA-based microarray analysis. J Biol Chem. 2002;277:4465-4476.
72. Tocci MJ, Matkovich DA, Collier KA, et al. The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes. J Immunol. 1989;143:718-726.
73. Mao Z, Wiedmann M. Calcineurin enhances MEF2 DNA binding activity in calcium-dependent survival of cerebellar granule neurons. J Biol Chem. 1999;274:31102-31107.
74. Pan F, Ye Z, Cheng L, et al. Myocyte enhancer factor 2 mediates calcium-dependent transcription of the interleukin-2 gene in T lymphocytes: a calcium signaling module that is distinct from but collaborates with the nuclear factor of activated T cells (NFAT). J Biol Chem. 2004;279:14477-14480.
75. Kuinose M, Iwagaki H, Morimoto Y, et al. Calcineurin antagonists inhibit interferon-gamma production by downregulation of interleukin-18 in human mixed lymphocyte reactions. Acta Med Okayama. 2000;54:201-209.
76. Luo C, Burgeon E, Carew JA, et al. Recombinant NFAT1 (NFATp) is regulated by calcineurin in T cells and mediates transcription of several cytokine genes. Mol Cell Biol. 1996;16:3955-3966.
77. Mori A, Suko M, Nishizaki Y, et al. IL-5 production by CD4+ T cells of asthmatic patients is suppressed by glucocorticoids and the immunosuppressants FK506 and cyclosporin A. Int Immunol. 1995;7:449-457.
78. Sakuma S, Kato Y, Nishigaki F, et al. FK506 potently inhibits T cell activation induced TNF-alpha and IL-1beta production in vitro by human peripheral blood mononuclear cells. Br J Pharmacol. 2000;130:1655-1663.
79. Dumont FJ. FK506 enhances IL-13 production by T cells activated through CD3/CD28. Int Arch Allergy Immunol. 1997;114:300-301.
80. Takamatsu Y, Hasegawa M, Sato S, et al. IL-13 production by peripheral blood mononuclear cells from patients with atopic dermatitis. Dermatology. 1998;196:377-381.
81. Khanna A, Cairns V, Hosenpud JD. Tacrolimus induces increased expression of transforming growth factor-beta1 in mammalian lymphoid as well as nonlymphoid cells. Transplantation. 1999;67:614-619.
82. Tanigawa T, Pai R, Arakawa T, et al. TGF-beta signaling pathway: its role in gastrointestinal pathophysiology and modulation of ulcer healing. J Physiol Pharmacol. 2005;56:3-13.
83. Schaffer M, Fuchs N, Volker J, et al. Differential effect of tacrolimus on dermal and intestinal wound healing. J Invest Surg. 2005;18:71-79.
84. Monteleone G, Pallone F, MacDonald TT. Smad7 in TGF-beta-mediated negative regulation of gut inflammation. Trends Immunol. 2004;25:513-517.
85. Schwaninger M, Blume R, Kruger M, et al. Involvement of the Ca(2+)-dependent phosphatase calcineurin in gene transcription that is stimulated by cAMP through cAMP response elements. J Biol Chem. 1995;270:8860-8866.
86. Cos J, Villalba T, Parra R, et al. FK506 in the maturation of dendritic cells. Haematologica. 2002;87:679-687.
87. Tiefenthaler M, Hofer S, Ebner S, et al. In vitro treatment of dendritic cells with tacrolimus: impaired T-cell activation and IP-10 expression. Nephrol Dial Transplant. 2004;19:553-560.
88. Walliser P, Benzie CR, Kay JE. Inhibition of murine B-lymphocyte proliferation by the novel immunosuppressive drug FK-506. Immunology. 1989;68:434-435.
89. Hamalainen M, Lahti A, Moilanen E. Calcineurin inhibitors, cyclosporin A and tacrolimus inhibit expression of inducible nitric oxide synthase in colon epithelial and macrophage cell lines. Eur J Pharmacol. 2002;448:239-244.
90. Strestikova P, Otova B, Filipec M, et al. Inhibitory effect of FK 506 and cyclosporin A on nitric oxide production by LPS-treated cultured rat macrophages. Physiol Res. 2000;49:725-728.
91. Elitsur Y, Liu X, Dosescu J, et al. FK-506 and cyclosporine A (CsA) immunomodulation of the human gut mucosal immune system. Dig Dis Sci. 1995;40:1934-1940.
92. Aiko S, Conner EM, Fuseler JA, et al. Effects of cyclosporine or FK506 in chronic colitis. J Pharmacol Exp Ther. 1997;280:1075-1084.
93. Hoshino H, Goto H, Sugiyama S, et al. Effects of FK506 on an experimental model of colitis in rats. Aliment Pharmacol Ther. 1995;9:301-307.
94. Takizawa H, Shintani N, Natsui M, et al. Activated immunocompetent cells in rat colitis mucosa induced by dextran sulfate sodium and not complete but partial suppression of colitis by FK506. Digestion. 1995;56:259-264.
95. Hogenauer C, Wenzl HH, Hinterleitner TA, et al. Effect of oral tacrolimus (FK 506) on steroid-refractory moderate/severe ulcerative colitis. Aliment Pharmacol Ther. 2003;18:415-423.
96. Fellermann K, Tanko Z, Herrlinger KR, et al. Response of refractory colitis to intravenous or oral tacrolimus (FK506). Inflamm Bowel Dis. 2002;8:317-324.
97. Baumgart DC, Wiedenmann B, Dignass AU. Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease. Aliment Pharmacol Ther. 2003;17:1273-1281.
98. Bousvaros A, Kirschner BS, Werlin SL, et al. Oral tacrolimus treatment of severe colitis in children. J Pediatr. 2000;137:794-799.
99. Ierardi E, Principi M, Francavilla R, et al. Oral tacrolimus long-term therapy in patients with Crohn's disease and steroid resistance. Aliment Pharmacol Ther. 2001;15:371-377.
100. Lowry PW, Weaver AL, Tremaine WJ, et al. Combination therapy with oral tacrolimus (FK506) and azathioprine or 6-mercaptopurine for treatment-refractory Crohn's disease perianal fistulae. Inflamm Bowel Dis. 1999;5:239-245.
101. Sandborn WJ, Present DH, Isaacs KL, et al. Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial. Gastroenterology. 2003;125:380-388.
102. de Oca J, Vilar L, Castellote J, et al. Immunomodulation with tacrolimus (FK506): results of a prospective, open-label, non-controlled trial in patients with inflammatory bowel disease. Rev Esp Enferm Dig. 2003;95:465-470.
103. Casson DH, Eltumi M, Tomlin S, et al. Topical tacrolimus may be effective in the treatment of oral and perineal Crohn's disease. Gut. 2000;47:436-440.
104. Kapturczak MH, Meier-Kriesche HU, Kaplan B. Pharmacology of calcineurin antagonists. Transplant Proc. 2004;36:25S-32S.
105. Allegra CJ, Chabner BA, Drake JC, et al. Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates.. J Biol Chem. 1985;260:9720-9726.
106. Allegra CJ, Drake JC, Jolivet J, et al. Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates. Proc Natl Acad Sci U S A. 1985;82:4881-4885.
107. Sant ME, Lyons SD, Phillips L, et al. Antifolates induce inhibition of amido phosphoribosyltransferase in leukemia cells. J Biol Chem. 1992;267:11038-11045.
108. Genestier L, Paillot R, Quemeneur L, et al. Mechanisms of action of methotrexate. Immunopharmacology. 2000;47:247-257.
109. Wascher TC, Hermann J, Brezinschek HP, et al. Cell-type specific response of peripheral blood lymphocytes to methotrexate in the treatment of rheumatoid arthritis. Clin Invest. 1994;72:535-540.
110. Graffner-Nordberg M, Fyfe M, Brattsand R, et al. Design and synthesis of dihydrofolate reductase inhibitors encompassing a bridging ester group. Evaluation in a mouse colitis model. J Med Chem. 2003;46:3455-3462.
111. Ortiz Z, Shea B, Suarez-Almazor ME, et al. The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A metaanalysis of randomized controlled trials. J Rheumatol. 1998;25:36-43.
112. Morgan SL, Baggott JE, Vaughn WH, et al. The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 1990;33:9-18.
113. Fairbanks LD, Ruckemann K, Qiu Y, et al. Methotrexate inhibits the first committed step of purine biosynthesis in mitogen-stimulated human T-lymphocytes: a metabolic basis for efficacy in rheumatoid arthritis? Biochem J. 1999;342(Pt 1):143-152.
114. Constantin A, Loubet-Lescoulie P, Lambert N, et al. Antiinflammatory and immunoregulatory action of methotrexate in the treatment ofrheumatoid arthritis: evidence of increased interleukin-4 and interleukin-10 gene expression demonstrated in vitro by competitive reverse transcriptase-polymerase chain reaction. Arthritis Rheum. 1998;41:48-57.
115. Friesen C, Herr I, Krammer PH, et al. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med. 1996;2:574-577.
116. Strauss G, Osen W, Debatin KM. Induction of apoptosis and modulation of activation and effector function in T cells by immunosuppressive drugs. Clin Exp Immunol. 2002;128:255-266.
117. Izeradjene K, Revillard JP, Genestier L. Inhibition of thymidine synthesis by folate analogues induces a Fas-Fas ligand-independent deletion of superantigen-reactive peripheral T cells. Int Immunol. 2001;13:85-93.
118. Genestier L, Paillot R, Fournel S, et al. Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J Clin Invest. 1998;102:322-328.
119. Paillot R, Genestier L, Fournel S, et al. Activation-dependent lymphocyte apoptosis induced by methotrexate. Transplant Proc. 1998;30:2348-2350.
120. Johnston A, Gudjonsson JE, Sigmundsdottir H, et al. The antiinflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules. Clin Immunol. 2005;114:154-163.
121. Yamasaki E, Soma Y, Kawa Y, et al. Methotrexate inhibits proliferation and regulation of the expression of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 by cultured human umbilical vein endothelial cells. Br J Dermatol. 2003;149:30-38.
122. Ciesielski CJ, Pflug JJ, Mei J, et al. Methotrexate regulates ICAM-1 expression in recipients of rat cardiac allografts. Transpl Immunol. 1998;6:111-121.
123. Bouma MG, van den Wildenberg FA, Buurman WA. Adenosine inhibits cytokine release and expression of adhesion molecules by activated human endothelial cells. Am J Physiol. 1996;270:C522-C529.
124. Yamauchi Y, Okazaki H, Desaki M, et al. Methotrexate induces interleukin-8 production by human bronchial and alveolar epithelial cells. Clin Sci (Lond). 2004;106:619-625.
125. Li W, Bertino JR. Fas-mediated signaling enhances sensitivity of human soft tissue sarcoma cells to anticancer drugs by activation of p38 kinase. Mol Cancer Ther. 2002;1:1343-1348.
126. Kobayashi K, Terada C, Tsukamoto I. Methotrexate-induced apoptosis in hepatocytes after partial hepatectomy. Eur J Pharmacol. 2002;438:19-24.
127. Majumdar S, Aggarwal BB. Methotrexate suppresses NF-kappaB activation through inhibition of IkappaBalpha phosphorylation and degradation. J Immunol. 2001;167:2911-2920.
128. Durez P, Appelboom T, Vray B, et al. Methotrexate inhibits LPS-induced tumor necrosis factor production in vivo. Eur Cytokine Network. 1998;9:669-672.
129. Yamaki K, Uchida H, Harada Y, et al. Effect of methotrexate on Th1 and Th2 immune responses in mice. J Pharm Pharmacol. 2003;55:1661-1666.
130. Hildner K, Finotto S, Becker C, et al. Tumour necrosis factor (TNF) production by T cell receptor-primed T lymphocytes is a target for low dose methotrexate in rheumatoid arthritis. Clin Exp Immunol. 1999;118:137-146.
131. Becker C, Barbulescu K, Hildner K, et al. Activation and methotrexate-mediated suppression of the TNF alpha promoter in T cells and macrophages. Ann N Y Acad Sci. 1998;859:311-314.
132. Rudwaleit M, Yin Z, Siegert S, et al. Response to methotrexate in early rheumatoid arthritis is associated with a decrease of T cell derived tumour necrosis factor alpha, increase of interleukin 10, and predicted by the initial concentration of interleukin 4. Ann Rheum Dis. 2000;59:311-314.
133. Sajjadi FG, Takabayashi K, Foster AC, et al. Inhibition of TNF-alpha expression by adenosine: role of A3 adenosine receptors. J Immunol. 1996;156:3435-3442.
134. Parmely MJ, Zhou WW, Edwards CK III, et al. Adenosine and a related carbocyclic nucleoside analogue selectively inhibit tumor necrosis factor-alpha production and protect mice against endotoxin challenge. J Immunol. 1993;151:389-396.
135. Hildner K, Marker-Hermann E, Schlaak JF, et al. Azathioprine, mycophenolate mofetil, and methotrexate specifically modulate cytokine production by T cells. Ann N Y Acad Sci. 1998;859:204-207.
136. Seitz M, Zwicker M, Wider B. Enhanced in vitro induced production of interleukin 10 by peripheral blood mononuclear cells in rheumatoid arthritis is associated with clinical response to methotrexate treatment. J Rheumatol. 2001;28:496-501.
137. Cronstein BN, Naime D, Ostad E. The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest. 1993;92:2675-2682.
138. Baggott JE, Morgan SL, Ha TS, et al. Antifolates in rheumatoid arthritis: a hypothetical mechanism of action. Clin Exp Rheumatol. 1993;11:S101-S105.
139. Sundaram U, Hassanain H, Suntres Z, et al. Rabbit chronic ileitis leads to up-regulation of adenosine A1/A3 gene products, oxidative stress, and immune modulation. Biochem Pharmacol. 2003;65:1529-1538.
140. Cronstein BN, Rosenstein ED, Kramer SB, et al. Adenosine; a physiologic modulator of superoxide anion generation by human neutrophils. Adenosine acts via an A2 receptor on human neutrophils. J Immunol. 1985;135:1366-1371.
141. McWhinney CD, Dudley MW, Bowlin TL, et al. Activation of adenosine A3 receptors on macrophages inhibits tumor necrosis factor-alpha. Eur J Pharmacol. 1996;310:209-216.
142. Jacobson KA. Adenosine A3 receptors: novel ligands and paradoxical effects. Trends Pharmacol Sci. 1998;19:184-191.
143. Hasko G, Szabo C, Nemeth ZH, et al. Adenosine receptor agonists differentially regulate IL-10, TNF-alpha, and nitric oxide production in RAW 264.7 macrophages and in endotoxemic mice. J Immunol. 1996;157:4634-4640.
144. Le Moine O, Stordeur P, Schandene L, et al. Adenosine enhances IL-10 secretion by human monocytes. J Immunol. 1996;156:4408-4414.
145. Bouma MG, Stad RK, van den Wildenberg FA, et al. Differential regulatory effects of adenosine on cytokine release by activated human monocytes. J Immunol. 1994;153:4159-4168.
146. Szabo C, Scott GS, Virag L, et al. Suppression of macrophage inflammatory protein (MIP)-1alpha production and collagen-induced arthritis by adenosine receptor agonists. Br J Pharmacol. 1998;125:379-387.
147. Siegmund B, Rieder F, Albrich S, et al. Adenosine kinase inhibitor GP515 improves experimental colitis in mice. J Pharmacol Exp Ther. 2001;296:99-105.
148. Egan LJ, Sandborn WJ, Mays DC, et al. Plasma and rectal adenosine in inflammatory bowel disease: effect of methotrexate. Inflamm Bowel Dis. 1999;5:167-173.
149. Peulen O, Deloyer P, Deville C, et al. Polyamines in gut inflammation and allergy. Curr Med Chem. 2004;3:1-8.
150. Nesher G, Osborn TG, Moore TL. Effect of treatment with methotrexate, hydroxychloroquine, and prednisone on lymphocyte polyamine levels in rheumatoid arthritis: correlation with the clinical response and rheumatoid factor synthesis. Clin Exp Rheumatol. 1997;15:343-347.
151. Nesher G, Moore TL. The in vitro effects of methotrexate on peripheral blood mononuclear cells. Modulation by methyl donors and spermidine. Arthritis Rheum. 1990;33:954-959.
152. Flescher E, Bowlin TL, Talal N. Regulation of IL-2 production by mononuclear cells from rheumatoid arthritis synovial fluids. Clin Exp Immunol. 1992;87:435-437.
153. Watanabe S, Sato S, Nagase S, et al. Effects of methotrexate and cyclophosphamide on polyamine levels in various tissues of rats. J Drug Target. 1999;7:197-205.
154. Pfeffer LM, Yang CH, Murti A, et al. Polyamine depletion induces rapid NF-kappa B activation in IEC-6 cells. J Biol Chem. 2001;276:45909-45913.
155. Kozarek RA, Patterson DJ, Gelfand MD, et al. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med. 1989;110:353-356.
156. Baron TH, Truss CD, Elson CO. Low-dose oral methotrexate in refractory inflammatory bowel disease. Dig Dis Sci. 1993;38:1851-1856.
157. Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med. 1995;332:292-297.
158. Arora S, Katkov W, Cooley J, et al. Methotrexate in Crohn's disease: results of a randomized, double-blind, placebo-controlled trial. Hepatogastroenterology. 1999;46:1724-1729.
159. Chong RY, Hanauer SB, Cohen RD. Efficacy of parenteral methotrexate in refractory Crohn's disease. Aliment Pharmacol Ther. 2001;15:35-44.
160. Lemann M, Zenjari T, Bouhnik Y, et al. Methotrexate in Crohn's disease: long-term efficacy and toxicity. Am J Gastroenterol. 2000;95:1730-1734.
161. Vandeputte L, D'Haens G, Baert F, et al. Methotrexate in refractory Crohn's disease. Inflamm Bowel Dis. 1999;5:11-15.
162. Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med. 2000;342:1627-1632.
163. Mate-Jimenez J, Hermida C, Cantero-Perona J, et al. 6-Mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2000;12:1227-1233.
164. Ardizzone S, Bollani S, Manzionna G, et al. Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomised, investigator-blind study. Dig Liver Dis. 2003;35:619-627.
165. Mate-Jimenez J, Hermida C, Cantero-Perona J, et al. 6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2000;12:1227-1233.
166. Schroder O, Blumenstein I, Schulte-Bockholt A, et al. Combining infliximab and methotrexate in fistulizing Crohn's disease resistant or intolerant to azathioprine. Aliment Pharmacol Ther. 2004;19:295-301.
167. Fraser AG. Methotrexate: first-line or second-line immunomodulator? Eur J Gastroenterol Hepatol. 2003;15:225-231.
168. Paoluzi OA, Pica R, Marcheggiano A, et al. Azathioprine or methotrexate in the treatment of patients with steroid-dependent or steroid-resistant ulcerative colitis: results of an open-label study on efficacy and tolerability in inducing and maintaining remission. Aliment Pharmacol Ther. 2002;16:1751-1759.
169. Oren R, Arber N, Odes S, et al. Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology. 1996;110:1416-1421.
170. Kurnik D, Loebstein R, Fishbein E, et al. Bioavailability of oral vs. subcutaneous low-dose methotrexate in patients with Crohn's disease. Aliment Pharmacol Ther. 2003;18:57-63.
171. Te HS, Schiano TD, Kuan SF, et al. Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease. Am J Gastroenterol. 2000;95:3150-3156.
172. Alfadhli AA, McDonald JW, Feagan BG. Methotrexate for induction of remission in refractory Crohn's disease. Cochrane Database Syst Rev. 2005:CD003459.
173. Schroder O, Stein J. Low dose methotrexate in inflammatory bowel disease: current status and future directions. Am J Gastroenterol. 2003;98:530-537.
174. McDiarmid SV. Mycophenolate mofetil as induction therapy after liver transplantation. Liver Transpl Surg. 1999;5:85-89.
175. Basara N, Blau WI, Kiehl MG, et al. Mycophenolate mofetil for the prophylaxis of acute GVHD in HLA-mismatched bone marrow transplant patients. Clin Transplant. 2000;14:121-126.
176. Waiser J, Budde K, Braasch E, et al. Treatment of acute c-ANCA-positive vasculitis with mycophenolate mofetil. Am J Kidney Dis. 1999;34:e9.
177. Liu V, Mackool BT. Mycophenolate in dermatology. J Dermatol Treat. 2003;14:203-211.
178. Bijl M, Horst G, Bootsma H, et al. Mycophenolate mofetil prevents a clinical relapse in patients with systemic lupus erythematosus at risk. Ann Rheum Dis. 2003;62:534-539.
179. Allison AC. Mechanisms of action of mycophenolate mofetil in preventing chronic rejection. Transplant Proc. 2002;34:2863-2866.
180. Eugui EM, Mirkovich A, Allison AC. Lymphocyte-selective antiproliferative and immunosuppressive activity of mycophenolic acid and its morpholinoethyl ester (RS-61443) in rodents. Transplant Proc. 1991;23:15-18.
181. Colic M, Stojic-Vukanic Z, Pavlovic B, et al. Mycophenolate mofetil inhibits differentiation, maturation and allostimulatory function of human monocyte-derived dendritic cells. Clin Exp Immunol. 2003;134:63-69.
182. Jonsson CA, Erlandsson M, Svensson L, et al. Mycophenolate mofetil ameliorates perivascular T lymphocyte inflammation and reduces the double-negative T cell population in SLE-prone MRLlpr/lpr mice. Cell Immunol. 1999;197:136-144.
183. Jonsson CA, Carlsten H. Mycophenolic acid inhibits inosine 5-monophosphate dehydrogenase and suppresses immunoglobulin and cytokine production of B cells. Int Immunopharmacol. 2003;3:31-37.
184. Neurath MF, Wanitschke R, Peters M, et al. Mycophenolate mofetil for treatment of active inflammatory bowel disease. Clinical and immunological studies. Ann N Y Acad Sci. 1998;859:315-318.
185. Rentenaar RJ, van Diepen FN, Meijer RT, et al. Immune responsiveness in renal transplant recipients: mycophenolic acid severely depresses humoral immunity in vivo. Kidney Int. 2002;62:319-328.
186. Takahashi K, Reynolds M, Ogawa N, et al. Augmentation of T-cell apoptosis by immunosuppressive agents. Clin Transplant. 2004;18:72-75.
187. Cohn RG, Mirkovich A, Dunlap B, et al. Mycophenolic acid increases apoptosis, lysosomes and lipid droplets in human lymphoid and monocytic cell lines. Transplantation. 1999;68:411-418.
188. Izeradjene K, Revillard JP. Apoptosis of superantigen-activated T cells induced by mycophenolate mofetil treatment. Transplantation. 2001;71:118-125.
189. Quemeneur L, Gerland LM, Flacher M, et al. Differential control of cell cycle, proliferation, and survival of primary T lymphocytes by purine and pyrimidine nucleotides. J Immunol. 2003;170:4986-4995.
190. Hauser IA, Johnson DR, Thevenod F, et al. Effect of mycophenolic acid on TNF alpha-induced expression of cell adhesion molecules in human venous endothelial cells in vitro. Br J Pharmacol. 1997;122:1315-1322.
191. Mehling A, Grabbe S, Voskort M, et al. Mycophenolate mofetil impairs the maturation and function of murine dendritic cells. J Immunol. 2000;165:2374-2381.
192. Leckel K, Beecken WD, Jonas D, et al. The immunosuppressive drug mycophenolate mofetil impairs the adhesion capacity of gastrointestinal tumour cells. Clin Exp Immunol. 2003;134:238-245.
193. Glomsda BA, Blaheta RA, Hailer NP. Inhibition of monocyte/ endothelial cell interactions and monocyte adhesion molecule expression by the immunosuppressant mycophenolate mofetil. Spinal Cord. 2003;41:610-619.
194. Blaheta RA, Leckel K, Wittig B, et al. Inhibition of endothelial receptor expression and of T-cell ligand activity by mycophenolate mofetil. Transpl Immunol. 1998;6:251-259.
195. Blaheta RA, Leckel K, Wittig B, et al. Mycophenolate mofetil impairs transendothelial migration of allogeneic CD4 and CD8 T-cells. Transplant Proc. 1999;31:1250-1252.
196. Allison AC, Kowalski WJ, Muller CJ, et al. Mycophenolic acid and brequinar, inhibitors of purine and pyrimidine synthesis, block the glycosylation of adhesion molecules. Transplant Proc. 1993;25:67-70.
197. Durez P, Appelboom T, Pira C, et al. Antiinflammatory properties of mycophenolate mofetil in murine endotoxemia: inhibition of TNF-alpha and upregulation of IL-10 release. Int J Immunopharmacol. 1999;21:581-587.
198. Leon F, Smythies LE, Smith PD, et al. Involvement of dendritic cells in the pathogenesis of inflammatory bowel disease. In: Blumberg RS, Neurath MF, eds. Immune Mechanisms in Inflammatory Bowel Disease. New York: Springer Science, Landes Bioscience, 2005:117-133.
199. Van Parijs L, Perez VL, Biuckians A, et al. Role of interleukin 12 andcostimulators in T cell anergy in vivo. J Exp Med. 1997;186:1119-1128.
200. Miehsler W, Reinisch W, Moser G, et al. Is mycophenolate mofetil an effective alternative in azathioprine-intolerant patients with chronic active Crohn's disease? Am J Gastroenterol. 2001;96:782-787.
201. Fickert P, Hinterleitner TA, Wenzl HH, et al. Mycophenolate mofetil in patients with Crohn's disease. Am J Gastroenterol. 1998;93:2529-2532.
202. Hassard PV, Vasiliauskas EA, Kam LY, et al. Efficacy of mycophenolate mofetil in patients failing 6-mercaptopurine or azathioprine therapy for Crohn's disease. Inflamm Bowel Dis. 2000;6:16-20.
203. Skelly MM, Logan RF, Jenkins D, et al. Toxicity of mycophenolate mofetil in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2002;8:93-97.
204. Orth T, Peters M, Schlaak JF, et al. Mycophenolate mofetil versus azathioprine in patients with chronic active ulcerative colitis: a 12-month pilot study. Am J Gastroenterol. 2000;95:1201-1207.
205. Fellermann K, Steffen M, Stein J, et al. Mycophenolate mofetil: lack of efficacy in chronic active inflammatory bowel disease. Aliment Pharmacol Ther. 2000;14:171-176.
206. Cox VC, Ensom MH. Mycophenolate mofetil for solid organ transplantation: does the evidence support the need for clinical pharmacokinetic monitoring? Ther Drug Monit. 2003;25:137-157.
207. Banerjee R, Halil O, Bain BJ, et al. Neutrophil dysplasia caused by mycophenolatemofetil. Transplantation. 2000;70:1608-1610.
208. Cohen SM. Current immunosuppression in liver transplantation. Am J Ther. 2002;9:119-125.
209. Leighton JA. Cyclosporine, or cyclosporine not, for severe ulcerative colitis. Inflamm Bowel Dis. 2001;7:350-352.
210. Strober W, Fuss IJ, Blumberg RS. The immunology of mucosal models of inflammation. Annu Rev Immunol. 2002;20:495-549.
211. Coombes JL, Robinson NJ, Maloy KJ, et al. Regulatory T cells and intestinal homeostasis. Immunol Rev. 2005;204:184-194.
212. Fuss IJ, Heller F, Boirivant M, et al. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest. 2004;113:1490-1497.